These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 25665805)

  • 1. Pharmacology of basimglurant (RO4917523, RG7090), a unique metabotropic glutamate receptor 5 negative allosteric modulator in clinical development for depression.
    Lindemann L; Porter RH; Scharf SH; Kuennecke B; Bruns A; von Kienlin M; Harrison AC; Paehler A; Funk C; Gloge A; Schneider M; Parrott NJ; Polonchuk L; Niederhauser U; Morairty SR; Kilduff TS; Vieira E; Kolczewski S; Wichmann J; Hartung T; Honer M; Borroni E; Moreau JL; Prinssen E; Spooren W; Wettstein JG; Jaeschke G
    J Pharmacol Exp Ther; 2015 Apr; 353(1):213-33. PubMed ID: 25665805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabotropic glutamate receptor 5 negative allosteric modulators: discovery of 2-chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]pyridine (basimglurant, RO4917523), a promising novel medicine for psychiatric diseases.
    Jaeschke G; Kolczewski S; Spooren W; Vieira E; Bitter-Stoll N; Boissin P; Borroni E; Büttelmann B; Ceccarelli S; Clemann N; David B; Funk C; Guba W; Harrison A; Hartung T; Honer M; Huwyler J; Kuratli M; Niederhauser U; Pähler A; Peters JU; Petersen A; Prinssen E; Ricci A; Rueher D; Rueher M; Schneider M; Spurr P; Stoll T; Tännler D; Wichmann J; Porter RH; Wettstein JG; Lindemann L
    J Med Chem; 2015 Feb; 58(3):1358-71. PubMed ID: 25565255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Basimglurant for treatment of major depressive disorder: a novel negative allosteric modulator of metabotropic glutamate receptor 5.
    Fuxe K; Borroto-Escuela DO
    Expert Opin Investig Drugs; 2015; 24(9):1247-60. PubMed ID: 26219727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CTEP: a novel, potent, long-acting, and orally bioavailable metabotropic glutamate receptor 5 inhibitor.
    Lindemann L; Jaeschke G; Michalon A; Vieira E; Honer M; Spooren W; Porter R; Hartung T; Kolczewski S; Büttelmann B; Flament C; Diener C; Fischer C; Gatti S; Prinssen EP; Parrott N; Hoffmann G; Wettstein JG
    J Pharmacol Exp Ther; 2011 Nov; 339(2):474-86. PubMed ID: 21849627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)-1-methyl-1H-imidazole-4-carboxamide (THIIC), a novel metabotropic glutamate 2 potentiator with potential anxiolytic/antidepressant properties: in vivo profiling suggests a link between behavioral and central nervous system neurochemical changes.
    Fell MJ; Witkin JM; Falcone JF; Katner JS; Perry KW; Hart J; Rorick-Kehn L; Overshiner CD; Rasmussen K; Chaney SF; Benvenga MJ; Li X; Marlow DL; Thompson LK; Luecke SK; Wafford KA; Seidel WF; Edgar DM; Quets AT; Felder CC; Wang X; Heinz BA; Nikolayev A; Kuo MS; Mayhugh D; Khilevich A; Zhang D; Ebert PJ; Eckstein JA; Ackermann BL; Swanson SP; Catlow JT; Dean RA; Jackson K; Tauscher-Wisniewski S; Marek GJ; Schkeryantz JM; Svensson KA
    J Pharmacol Exp Ther; 2011 Jan; 336(1):165-77. PubMed ID: 20947638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DSR-98776, a novel selective mGlu5 receptor negative allosteric modulator with potent antidepressant and antimanic activity.
    Kato T; Takata M; Kitaichi M; Kassai M; Inoue M; Ishikawa C; Hirose W; Yoshida K; Shimizu I
    Eur J Pharmacol; 2015 Jun; 757():11-20. PubMed ID: 25823809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Negative allosteric modulation of metabotropic glutamate receptor 5 results in broad spectrum activity relevant to treatment resistant depression.
    Hughes ZA; Neal SJ; Smith DL; Sukoff Rizzo SJ; Pulicicchio CM; Lotarski S; Lu S; Dwyer JM; Brennan J; Olsen M; Bender CN; Kouranova E; Andree TH; Harrison JE; Whiteside GT; Springer D; O'Neil SV; Leonard SK; Schechter LE; Dunlop J; Rosenzweig-Lipson S; Ring RH
    Neuropharmacology; 2013 Mar; 66():202-14. PubMed ID: 22551786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurophysiological signals as potential translatable biomarkers for modulation of metabotropic glutamate 5 receptors.
    Harvey BD; Siok CJ; Kiss T; Volfson D; Grimwood S; Shaffer CL; Hajós M
    Neuropharmacology; 2013 Dec; 75():19-30. PubMed ID: 23831682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Partial mGlu₅ Negative Allosteric Modulators Attenuate Cocaine-Mediated Behaviors and Lack Psychotomimetic-Like Effects.
    Gould RW; Amato RJ; Bubser M; Joffe ME; Nedelcovych MT; Thompson AD; Nickols HH; Yuh JP; Zhan X; Felts AS; Rodriguez AL; Morrison RD; Byers FW; Rook JM; Daniels JS; Niswender CM; Conn PJ; Emmitte KA; Lindsley CW; Jones CK
    Neuropsychopharmacology; 2016 Mar; 41(4):1166-78. PubMed ID: 26315507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism based neurotoxicity of mGlu5 positive allosteric modulators--development challenges for a promising novel antipsychotic target.
    Parmentier-Batteur S; Hutson PH; Menzel K; Uslaner JM; Mattson BA; O'Brien JA; Magliaro BC; Forest T; Stump CA; Tynebor RM; Anthony NJ; Tucker TJ; Zhang XF; Gomez R; Huszar SL; Lambeng N; Fauré H; Le Poul E; Poli S; Rosahl TW; Rocher JP; Hargreaves R; Williams TM
    Neuropharmacology; 2014 Jul; 82():161-73. PubMed ID: 23291536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding Exposure-Receptor Occupancy Relationships for Metabotropic Glutamate Receptor 5 Negative Allosteric Modulators across a Range of Preclinical and Clinical Studies.
    Bennett KA; Sergeev E; MacSweeney CP; Bakker G; Cooper AE
    J Pharmacol Exp Ther; 2021 Apr; 377(1):157-168. PubMed ID: 33541889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of the mGluR5-NAM Basimglurant on Behavior in Adolescents and Adults with Fragile X Syndrome in a Randomized, Double-Blind, Placebo-Controlled Trial: FragXis Phase 2 Results.
    Youssef EA; Berry-Kravis E; Czech C; Hagerman RJ; Hessl D; Wong CY; Rabbia M; Deptula D; John A; Kinch R; Drewitt P; Lindemann L; Marcinowski M; Langland R; Horn C; Fontoura P; Santarelli L; Quiroz JA;
    Neuropsychopharmacology; 2018 Feb; 43(3):503-512. PubMed ID: 28816242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detailed In Vitro Pharmacological Characterization of Clinically Tested Negative Allosteric Modulators of the Metabotropic Glutamate Receptor 5.
    Arsova A; Møller TC; Vedel L; Hansen JL; Foster SR; Gregory KJ; Bräuner-Osborne H
    Mol Pharmacol; 2020 Jul; 98(1):49-60. PubMed ID: 32358164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical characterization of BRL 44408: antidepressant- and analgesic-like activity through selective alpha2A-adrenoceptor antagonism.
    Dwyer JM; Platt BJ; Rizzo SJ; Pulicicchio CM; Wantuch C; Zhang MY; Cummons T; Leventhal L; Bender CN; Zhang J; Kowal D; Lu S; Rajarao SJ; Smith DL; Shilling AD; Wang J; Butera J; Resnick L; Rosenzweig-Lipson S; Schechter LE; Beyer CE
    Int J Neuropsychopharmacol; 2010 Oct; 13(9):1193-205. PubMed ID: 20047711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population Pharmacokinetic and Exposure-dizziness Modeling for a Metabotropic Glutamate Receptor Subtype 5 Negative Allosteric Modulator in Major Depressive Disorder Patients.
    Cosson V; Schaedeli-Stark F; Arab-Alameddine M; Chavanne C; Guerini E; Derks M; Mallalieu NL
    Clin Transl Sci; 2018 Sep; 11(5):523-531. PubMed ID: 29877614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VU0477573: Partial Negative Allosteric Modulator of the Subtype 5 Metabotropic Glutamate Receptor with In Vivo Efficacy.
    Nickols HH; Yuh JP; Gregory KJ; Morrison RD; Bates BS; Stauffer SR; Emmitte KA; Bubser M; Peng W; Nedelcovych MT; Thompson A; Lv X; Xiang Z; Daniels JS; Niswender CM; Lindsley CW; Jones CK; Conn PJ
    J Pharmacol Exp Ther; 2016 Jan; 356(1):123-36. PubMed ID: 26503377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and optimization of 4,5,6,7-tetrahydrooxazolo[4,5-c]pyridines as potent and orally-active metabotropic glutamate receptor 5 negative allosteric modulators.
    Hirose W; Kato Y; Natsutani I; Takata M; Kitaichi M; Imai S; Hayashi S; Arai Y; Hoshino K; Yoshida K
    Bioorg Med Chem Lett; 2017 Sep; 27(18):4331-4335. PubMed ID: 28838696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blocking metabotropic glutamate receptor subtype 5 relieves maladaptive chronic stress consequences.
    Peterlik D; Stangl C; Bauer A; Bludau A; Keller J; Grabski D; Killian T; Schmidt D; Zajicek F; Jaeschke G; Lindemann L; Reber SO; Flor PJ; Uschold-Schmidt N
    Brain Behav Immun; 2017 Jan; 59():79-92. PubMed ID: 27524668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of the mTOR signaling pathway in the antidepressant-like activity of the mGlu5 antagonist MTEP and the mGlu7 agonist AMN082 in the FST in rats.
    Pałucha-Poniewiera A; Szewczyk B; Pilc A
    Neuropharmacology; 2014 Jul; 82():59-68. PubMed ID: 24631968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs.
    Palucha A; Pilc A
    Pharmacol Ther; 2007 Jul; 115(1):116-47. PubMed ID: 17582504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.